EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis

Rubén Solís-Armenta, Sergio Rodríguez-Rodríguez, Andrea Priscila Hernández-Pérez, Nidia Paulina-Zapata, Nancy Delgado, Efreen H Montano-Figueroa, Faustino Leyto, Juan Carlos Solís-Poblano, Andrés Gómez-De León, Lauro Fabian Amador, Carolina García-Castillo, Ramon Martínez-Hernández und 13 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05956-w ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Rubén Solís-Armenta und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Instituto Nacional De Cancerología, Mexico City, Mexico. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is the most frequent indication for allogeneic hematopoietic cell transplantation (alloHCT) worldwide; social and health system barriers limit its access. We performed an observational retrospective analysis in Mexico to analyze factors limiting alloHCT in fit patients with AML. With a median follow-up of 11.8 months, 301 patients were included, with a median age of 42; 33.5% were classified as adverse risk. Despite 215 patients (92.5%) achieving complete remission, only 103 (34%) had HLA-typing: 44.5% had a matched-sibling donor (MSD), 32% a haploidentical donor, and 23.5% had no donor. Only 23.5% of patients had an HCT consult; merely 36 underwent an HCT: 30 alloHCT, and six an autologous HCT. Age ≥ 60 years, HCT-CI score ≥ three, and the absence of a local transplant program negatively influenced HLA typing likelihood. Patients with an MSD had a higher alloHCT likelihood. The cumulative incidence of transplant (CIT) and relapse (CIR) at 6 and 12 months was 7.3% and 13.8%, 8.2% and 13%, respectively. A lack of HLA-typing was associated with a lower CIT (p < 0.001) and higher CIR (p = 0.033) (HR 11.72, CI 95% 4.39-31.27, p < 0.001), while the presence of an MSD was associated with a higher CIT (p = 0.002) (HR 4.22, CI 95% 1.89-9.44, p < 0.001). The main reasons hindering alloHCT are the lack of access to HLA-typing tests and the absence of an MSD. A national donor registry and improved HLA-typing accessibility are critical for increasing alloHCT access in Mexico.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansMexicoMiddle AgedMaleFemaleAdultRetrospective StudiesAgedAdolescentYoung AdultHistocompatibility TestingFollow-Up StudiesAllografts

Stichwörter der Autor:innen

Acute myeloid leukemiaDeveloping countriesHLA-typingHematopoietic cell transplantation

Autor:innen und Institutionen

  • Department of Hematology, Instituto Nacional De Cancerología, Mexico City, Mexico.
  • Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
  • Department of Hematology, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
  • Department of Hematology, Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Mexico.
  • Department of Hematology, Hospital Juarez de Mexico, Mexico City, Mexico.
  • Department of Hematology, Centro Medico Nacional Manuel Avila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico.

Zitieren

APA

Solís-Armenta, R., Rodríguez-Rodríguez, S., Hernández-Pérez, A. P., Paulina-Zapata, N., Delgado, N., Montano-Figueroa, E. H., Leyto, F., Solís-Poblano, J. C., Gómez-De León, A., Amador, L. F., García-Castillo, C., Martínez-Hernández, R., Saldaña-Velazquez, H. A., Valero-Saldaña, L. M., Terreros, E., Jimenez-Ochoa, M. A., Milán-Salvatierra, A., Colunga-Pedraza, P. R., Gómez-Almaguer, D., …, & Demichelis-Gómez, R. (2024). Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis. Annals of Hematology. https://doi.org/10.1007/s00277-024-05956-w

Vancouver

Solís-Armenta R, Rodríguez-Rodríguez S, Hernández-Pérez AP, Paulina-Zapata N, Delgado N, Montano-Figueroa EH, et al. Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis. Annals of Hematology. 2024. doi:10.1007/s00277-024-05956-w

BibTeX
@article{SolsArmenta2024,
  author = {Solís-Armenta, Rubén and Rodríguez-Rodríguez, Sergio and Hernández-Pérez, Andrea Priscila and Paulina-Zapata, Nidia and Delgado, Nancy and Montano-Figueroa, Efreen H and Leyto, Faustino and Solís-Poblano, Juan Carlos and Gómez-De León, Andrés and Amador, Lauro Fabian and García-Castillo, Carolina and Martínez-Hernández, Ramon and Saldaña-Velazquez, Hugo Alexis and Valero-Saldaña, Luis Manuel and Terreros, Eduardo and Jimenez-Ochoa, Marco Alejandro and Milán-Salvatierra, Andrea and Colunga-Pedraza, Perla Rocío and Gómez-Almaguer, David and Alcivar, Luisa M and Apodaca-Chávez, Elia and Meza, Mario and Yocupicio, Fabiola and Sánchez-Díaz, Susana and Demichelis-Gómez, Roberta},
  title = {Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05956-w}
}
Kostenlos starten →